These drugs preferentially block the ability of PARP1 and PARP2 to initiate repair of DNA damage and selectively kill cancer cells that are unable to repair double strand breaks based on the concept of synthetic lethality (2, 3). The gene discussed is PARP2; the disease is cancer.